Seems like Mayne is not good at communicating with the market, comparing with other Pharma companies. Still can't figure out why. I think it may be one of reasons below, or a combination of these. What do you think guys? 1. Weak investor relations. 2. Weak management. 3. Nothing big or small to report on? I doubt it, at least there are things in the pipeline and we can tell from Annual report. 4. Not enough pressure from the board and big players. 5. Due to the nature of the business, they can't release things, except for document submission and FDA approval? 6. Management incentive is not well structured, there are not enough incentives for management team to drive performance and share price. 7. They are simply not confident about Mayne's future and the way they are heading. 8. They don't care about short team shareholders, so no need for regular communications. Just wait for big news.
I am so confused about this company. At least if Mayne can keep up with the market like Mithra, I think for now, we are already in 60.
MYX Price at posting:
38.8¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)